Shenzhen Accord Pharmaceutical Co., Ltd.
The 3rd Quarterly Report for 2007

§1 Important Notes

1.1 Board of Directors and the Supervisory Committee of Shenzhen Accord Pharmaceutical Co., Ltd. (hereinafter referred to as the Company) and its directors, supervisors and senior executives hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.

1.2 No directors stated any objection for the correctness, accuracy and completeness of the contents of this report.

1.3 All directors attended the Board meeting.

1.4 The financial report of the 3rd Quarterly Report is unaudited in the report period..

1.5 Chairman of the Company Mr. Chen Weigang, General Manager Mr. Shi Jinming, Chief Financial Officer Mr. Wei Pingxiao and Financial Manager Mr. Chi Guoguang hereby confirm that the Financial Report enclosed in the 3rd Quarterly Report is authentic and complete.

§2 Company Profile

2.1 Main Accounting Highlights and Financial Indexes:

Unit: RMB

	At the end of the report period	At the end of the last year	Increase/decrease of the end of report period than that of the end of the last year (%)
Total assets	3,032,615,337.13	2,632,128,528.84	15.22%
Owners' equity (or Shareholders' equity)	479,204,984.69	401,880,141.09	19.24%
Net assets per share	1.66	1.39	19.42%
	Year begin to end of report period		Increase/decrease over the same period of the last year (%)
Net cash flow arising from operating activities	80,990,776.82		-54.84%
Net cash flow arising from operating activities per share	0.28		-54.84%
	In the report period	Year begin to end of report period	Increase/decrease of the report period than that of the same period of the last year (%)
Net profit	43,178,380.63	103,076,826.65	73.07%
Basic earnings per share	0.150	0.358	72.41%
Basic earnings per share after deducting non-recurring gains and losses	-	0.297	-
Diluted earnings per share	0.150	0.358	72.41%
Return on equity	9.01%	21.51%	119.23%

Return on equity after deducting non-recurring gains and losses	5.19%	17.87%	26.05%

Items of non-recurring gains and losses

Unit: RMB

Items of non-recurring gains and losses	Balance from year-begin to end of report period
Gains/losses from the disposal of non-current asset	25,165,486.92
Net income and expense from other non-operating activities	-188,072.79
Governmental subsidy	2,529,924.84
Income tax and influenced amount from the gains and losses of minority shareholders	-10,067,513.85
Total	17,439,825.12

2.2 Total number of shareholders in the end of the report period and shares held by the top ten shareholders with unrestricted conditions

Unit: Share

Total number of shareholders	25,852	
Shares held by the top ten shareholders with unrestricted conditions		
Full Name of shareholder	Amount of unrestricted shares held	Type of shares
AGRICULTURAL BANK OF CHINA-DACHENG INNOVATIVE GROWTH COMBINED SECURITIES INVESTMENT FUND	7,395,348	RMB common share
INDUSTRIAL AND COMMERCIAL BANK OF CHINA － PENGHUA EXCELLENT ADMINISTRATIVE STOCK SECURITIES INVESTMENT FUND	5,499,451	RMB common share
INDUSTRIAL BANK CO., LTD.- GUANGDA BAODEXIN BONUS STOCK SECURITIES INVESTMENT FUND	4,988,549	RMB common share
INDUSTRIAL AND COMMERCIAL BANK OF CHINA－BOSHI SELECTED STOCK SECURITIES INVESTMENT FUND	3,499,567	RMB common share
NATIONAL SOCIAL SECURITY FUND-ZERO AND NINE COMBINATION	3,441,997	RMB common share
BANK OF COMMUNICATIONS- PENGHUA CHINA FIFTY OPEN SECURITIES INVESTMENT FUND	3,258,560	RMB common share
BANK OF CHINA- YIFANGDA ACTIVE GROWTH SECURITIES INVESTMENT FUND	3,000,000	RMB common share
AJIA-LIGHTHORSE CHINA GROWTH MASTER FUND LIMITED	2,765,927	Domestically listed foreign share
CHINA CONSTRUCTION BANK-ZHONGXIN BONUS SELECTED STOCK SECURITIES INVESTMENT FUND	2,489,760	RMB common share
BANK OF CHINA- DACHENG FORTUNE ADMINISTRATION 2020 LIFE CYCLE SECURITIES INVESTMENT FUND	2,366,049	RMB common share

§3 Significant events

3.1 Particulars about material changes in items of main accounting statement and financial index, and explanations of reasons

√ Applicable ☐Inapplicable

I. From the beginning of the year to the end of this report period, the Company has realized net profit attributable to owners of the parent company amounting to RMB 103,080,000, an increase scope of 51.61% compared with the net profit of RMB 67,990,000 made in the same period of last year. The main reasons for the increase are listed as follows:

1. The conformity between Guangdong and Guangxi provinces made an apparent efficiency. The sale scope is enlarging. From the beginning of the year to the end of this report period, the Company has realized operating income of RMB 5,097,810,000, an increase scope of 26.25% compared with that of RMB 4,037,760,000 made in the same period of last year.

2. Strictly carrying out the expense budget and strengthening internal control, the Company and its subsidiary companies obtain efficiency in decreasing expense. From the beginning of the year to the end of this report period, expense for the Company amounts to RMB 394,100,000. While in the same period of last year, the expense was RMB 367,550,000 with the increase scope of 7.22%.

3. Through the sale of stock equity, the subsidiary company has received investment income. From the beginning of the year to the end of this report period, the Company has realized investment income of RMB 30,880,000. According to the investment income of RMB 6,850,000 made in the same period of last year, the increase scope reaches at 350.80%. The main reason for the big increase is that: Guangzhou South Medical Equipment Corporation---a wholly-owned subsidiary company of Sinopharm Medicine Holding Guangzhou Co., Ltd., which is a subsidiary holding company of the Company, sell out all the stock of National Medicine Group Medicine Co., Ltd held by them. And this makes investment income of RMB 25,590,000.

II. From the beginning of the year to the end of this report period, the tax expense for the Company is RMB 37, 250, 000, an increase scope of 45.92% compared with the tax expense of RMB 25,520,000 made in the same period of last year. The reasons for increase are as follows: at one side, the increase of main operating income brings the increase of total profit amount; at the other side, the subsidiary company gets investment income through selling stock equity, and then the tax expense increases RMB 8,440,000.

III. At the end of the report period, the account paid in advance has increased RMB 35,790,000 than that of last year. The increase scope is 114.4%. The main reason for this increase is that: Sinopharm Medicine Holding Guangzhou Co., Ltd. ---the Company’s subsidiary holding company, strengthens purchasing the products which were enjoyed high popularity in the market, and at the same time, some individual suppliers change the rate of account paid in advance for purchase.

IV. At the end of the report period, the investing property has declined of RMB 33,210,000 than that of last year. The decrease scope is 85.14%. The main reason for the decrease is that: with the consideration of the need of operation and administration, National Medicine Subsidiary Holding Guangzhou Co., Ltd---the Company’s subsidiary holding company, takes back the office building for self-using which was originally rented out. The total amount which is influenced is RMB 33,000,000.

V. At the end of the report period, the fixed assets have increased RMB 146,180,000 than that of last year. The increase scope is 66.27%. The projects-in-progress have decreased RMB 98,240,000 and the decrease scope is 65.06%. The reason for the increase of fixed assets are listed as follows: at one side, Sinopharm Medicine Holding Guangzhou Co., Ltd. ---the Company’s subsidiary holding company, transfers RMB 33,000,000 by investing property; at the other side, the project---Medicine Research and Development Base of Shenzhen Zhijun Pharmaceutical Co., Ltd, a subsidiary holding company of the Company, has transferred to the fixed assets of RMB 154,610,000 from its original project-in-progress.

VI. At the end of the report period, the deferred tax assets have decreased RMB 2,720,000 than that of last year. And the decrease scope is 33.65%. The main reason for the decrease is that: China Medicine (Group) Guangzhou Corporation and its subsidiary company---wholly-owned subsidiary companies by National Medicine Subsidiary Holding Guangzhou Co., Ltd--- the Company's subsidiary holding company, has transferred back deferred tax assets of RMB 2,620,000 from the gains of the current period, which can be used to make up the former annual losses.

3.2 Analysis and explanation of significant events and their influence and solutions

☐Applicable √ Inapplicable

3.3 Implementations of commitments by the Company, shareholders and actual controller

√ Applicable ☐Inapplicable

I. SINOPHARM MEDICINE HOLDING CO., LTD.

Commitments: (1) Not selling original non-tradable equities through stock exchange in 24 months from the day they become tradable. (2) Original non-tradable equities sold after the 24 months through stock exchange take up no more than 10% of the Company's total shares in the following 12 months, and the price is no lower than 110% of the stock weighted average price of the 30 trading days before Accord Pharmaceutical's Board of Directors publish the reform plan (from the day of implementing Non-tradable Shares Reform to the day when Sinopharm Medicine Holding sells equities, Ex Warrant/Ex Dividend on the price will be implemented if dividend, allotment or transferring of public capital to equity and so on happens).

Commitment implementation: Implementing

II. SHENZHEN BAOAN DISTRICT SHIYAN TOWN ECONOMIC AND DEVELOPMENT CORPORATION

Commitments: Not trading or selling equities within 12 months from the day when plan of Non-tradable Shares Reform is carried out; on basis of the aforementioned time limited, original non-tradable equities sold through stock exchange take up no more than 5% of the Company's total shares in the following 12 months; no mare than 10% within 24 months.

Commitment implementation: Implementing

3.4 Estimation of accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the warning of its material change compared with the corresponding period of the last year and explanation of reason

√ Applicable ☐Inapplicable

During the report period, the Company's subsidiary holding company has received amount of investment income from transferring stock equity; and at the same time, the main operating income has increased and the ability to make profit is advancing. Therefore, an estimation could be made from the beginning of the year to the end of the next report period, the accumulative net profit will increase 50%-100%than that in the same period of last year(New Accounting Standards is not used for adjusting).

3.5 Other significant events needed for explanations

3.5.1 Particulars about securities investment

☐Applicable √ Inapplicable

3.5.2 Equity of other listed companies held

☐Applicable √ Inapplicable

3.5.3 Equity of non-listed financial enterprises and planned listed companies held

☐Applicable √ Inapplicable

3.5.4 Registration form for receiving research, communication and interview in the report period.

√ Applicable ☐Inapplicable

Date	Place	Way	The received parties	Contents discussed and materials supplied
Sep.7, 2007	Accord Pharm. Bldg.	Spot investigation	China International Fund Management Co., Ltd.	Got to know the bidding of medicines to internet and development strategy of the Company, and no material was supplied.
Sep.11, 2007	Accord Pharm. Bldg.	Spot investigation	China Jianyi Investment Securities、Changjiang Securities、Citic Securities	Observed the Shareholders' General Meeting of the Company, and the meeting material was supplied.
Sep.21, 2007	Accord Pharm. Bldg.	Spot investigation	Fortis Haitong Investment Management Co., Ltd.	Got to know the medical industry, and no material was supplied.

§4 Appendix

4.1 Balance sheet

Prepared by Shenzhen Accord Pharmaceutical Co., Ltd Sep. 30, 2007 Unit: RMB

Items	Amount of period-end		Amount of period-begin	
	Consolidation	Parent Company	Consolidation	Parent Company
Current assets:				
Monetary funds	216,652,152.57	51,322,281.93	205,341,835.52	51,149,747.14
Settlement provisions				
Capital lent				
Transaction finance asset				
Notes receivable	183,267,424.65	1,068,134.88	207,461,757.47	27,417,436.43
Accounts receivable	1,391,093,981.61	319,483,941.84	1,134,397,089.98	232,925,656.56
Accounts in advance	67,068,147.55	5,983,389.47	31,281,294.12	3,932,363.78
Insurance receivable				
Reinsurance receivables				
Contract reserve of reinsurance receivable				
Interest receivable				
Other receivables	41,428,817.25	155,179,580.10	37,937,661.49	155,515,089.60
Purchase restituted finance asset				
Inventories	587,850,740.24	93,915,720.62	489,402,122.53	72,299,571.82

Non-current asset due within one year				
Other current assets				
Total current assets	2,487,361,263.87	626,953,048.84	2,105,821,761.11	543,239,865.33
Non-current assets:				
Granted loans and advances				
Finance asset available sales				
Held-to-maturity securities				
Long-term account receivable				
Long-term equity investment	54,953,497.11	340,194,504.04	53,916,718.03	440,707,272.12
Investment property	5,794,998.64	2,328,672.80	39,005,516.50	2,441,664.20
Fixed assets:	366,768,519.77	46,767,834.15	220,586,376.34	50,064,596.27
Construction in progress	52,750,520.66	253,886.24	150,990,967.55	253,886.24
Engineering material				
Disposal of fixed asset				
Consumable biological asset				
Oil and gas asset				
Intangible assets	30,959,945.37	29,580,818.96	32,031,022.36	30,444,684.41
Expense on Research and Development				
Goodwill				
Long-term expenses to be apportioned	13,983,575.24	5,175.00	6,155,684.69	122,397.20
Deferred income tax asset	5,357,705.67		8,074,635.35	
Other non-current asset	14,685,310.80		15,545,846.91	
Total non-current asset	545,254,073.26	419,130,891.19	526,306,767.73	524,034,500.44
Total assets	3,032,615,337.13	1,046,083,940.03	2,632,128,528.84	1,067,274,365.77
Current liabilities:				
Short-term loans	272,941,192.14	45,000,000.00	296,986,007.95	37,417,436.43
Loan from central bank				
Absorbing deposit and interbank deposit				
Capital borrowed				
Transaction financial liabilities				
Notes payable	562,520,947.59	124,569,798.00	419,175,924.81	110,205,719.50
Accounts payable	1,136,241,502.30	269,061,597.52	956,987,248.04	261,167,008.52
Accounts received in	21,983,036.79	56,378.51	30,835,803.43	26,057.63

advance				
Selling financial asset of repurchase				
Commission charge and commission payable				
Wage payable	61,020,035.74	17,386,355.14	81,661,118.72	18,263,253.67
Taxes payable	23,338,417.37	-2,970,622.58	3,220,047.64	3,682,359.72
Interest payable				
Dividends payable	3,889,895.26			
Other accounts payable	341,829,942.87	168,166,849.03	293,812,654.03	184,807,048.45
Reinsurance payables				
Insurance contract reserve				
Security trading of agency				
Security sales of agency				
Long-term liabilities due within 1 year				
Other current liabilities				
Total current liabilities	2,423,764,970.06	621,270,355.62	2,082,678,804.62	615,568,883.92
Non-current liabilities:				
Long-term loans	77,720,000.00		97,720,000.00	
Bonds payable				
Long-term account payable	658,319.59		1,054,352.56	
Special accounts payable	1,800,000.00	800,000.00	1,800,000.00	800,000.00
Projected liabilities				
Deferred income tax liabilities				
Other non-current liabilities	23,085,874.07		23,085,874.07	
Total non-current liabilities	103,264,193.66	800,000.00	123,660,226.63	800,000.00
Total liabilities	2,527,029,163.72	622,070,355.62	2,206,339,031.25	616,368,883.92
Owner’s equity (or shareholders’ equity):				
Paid-in capital (or share capital)	288,149,400.00	288,149,400.00	288,149,400.00	288,149,400.00
Capital public reserve	18,044,074.54	17,902,522.48	18,044,074.54	17,902,522.48
Less: Inventory shares				
Surplus public reserve	83,420,971.53	57,416,316.59	83,419,602.89	57,416,316.59
Provision of general risk				
Retained profit	89,590,538.62	60,545,345.34	12,267,063.66	87,437,242.78
Balance difference of foreign currency translation				

Total owner's equity attributable to parent company	479,204,984.69	424,013,584.41	401,880,141.09	450,905,481.85
Minority interests	26,381,188.72		23,909,356.50	
Total owner's equity	505,586,173.41	424,013,584.41	425,789,497.59	450,905,481.85
Total liabilities and owner's equity	3,032,615,337.13	1,046,083,940.03	2,632,128,528.84	1,067,274,365.77

4.2 Profit statement in the report period

Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. July-Sep., 2007 Unit: RMB

Items	This period		Same period of last year	
	Consolidation	Parent Company	Consolidation	Parent Company
I. Total operating income	1,855,582,230.75	319,468,697.25	1,377,232,047.55	309,819,970.62
Including: Operating income	1,855,582,230.75	319,468,697.25	1,377,232,047.55	309,819,970.62
Interest income				
Insurance gained				
Commission charge and commission income				
II. Total operating cost	1,819,811,214.54	319,049,317.21	1,345,532,011.580	313,228,005.68
Including: Operating cost	1,660,852,419.08	299,851,470.55	1,230,998,548.99	301,718,966.90
Interest expense				
Commission charge and commission expense				
Cash surrender value				
Net amount of expense of compensation				
Net amount of withdrawal of insurance contract reserve				
Bonus expense of guarantee slip				
Reinsurance expense				
Operating tax and extras	2,634,130.95	26,227.19	2,420,795.52	97,219.74
Sales expenses	93,037,884.38	9,231,478.62	63,767,378.89	4,140,385.35
Administration expenses	53,081,485.78	9,437,207.54	37,473,830.36	5,123,049.92
Financial expenses	8,716,551.20	249,381.19	6,936,979.07	656,748.39
Losses of devaluation of asset	1,488,743.15	253,552.12	3,934,478.75	1,491,635.38
Add: Changing income of fair value(Loss is listed with "-")				
Investment income (Loss is listed with "-")	27,902,981.36	-308,131.72	2,867,266.11	310,968.66
Including: Investment	-4,080,946.51	-308,131.72	-3,568,078.32	310,968.66

income on affiliated company and joint venture				
Exchange income (Loss is listed with "-")				
III. Operating profit (Loss is listed with "-")	63,673,997.57	111,248.32	34,567,302.08	-3,097,066.40
Add: Non-operating income	2,965,951.87	11,871.58	236,898.36	784.24
Less: Non-operating expense	121,379.20	42,823.50	274,580.98	3,241.41
Including: Disposal loss of non-current asset	580.80			
IV. Total Profit (Loss is listed with "-")	66,518,570.24	80,296.40	34,529,619.46	-3,099,523.57
Less: Income tax	20,183,853.23		7,994,315.55	
V. Net profit (Net loss is listed with "-")	46,334,717.01	80,296.40	26,535,303.91	-3,099,523.57
Net profit attributable to owner's equity of parent company	43,178,380.63	80,296.40	24,948,953.80	
Minority shareholders' gains and losses	3,156,336.38		1,586,350.11	
VI. Earnings per share				
i. Basic earnings per share	0.150		0.087	
ii. Diluted earnings per share	0.150		0.087	

4.3 Profit statement from year-begin to end of report period

Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Jan.-Sep., 2007 Unit: RMB

Items	This period		Same period of last year	
	Consolidation	Parent Company	Consolidation	Parent Company
I. Total operating income	5,097,814,185.29	948,750,941.08	4,037,763,523.58	900,740,619.30
Including: Operating income	5,097,814,185.29	948,750,941.08	4,037,763,523.58	900,740,619.30
Interest income				
Insurance gained				
Commission charge and commission income				
II. Total operating cost	4,983,926,137.06	948,678,904.33	3,946,422,630.43	907,573,180.82
Including: Operating cost	4,582,936,777.05	896,510,542.35	3,573,554,761.62	862,746,100.19
Interest expense				
Commission charge and commission expense				
Cash surrender value				
Net amount of expense of compensation				
Net amount of				

withdrawal of insurance contract reserve				
Bonus expense of guarantee slip				
Reinsurance expense				
Operating tax and extras	7,189,170.64	397,208.890	6,252,158.84	213,964.45
Sales expenses	239,554,554.11	23,207,662.520	229,734,294.01	15,040,071.08
Administration expenses	133,424,892.08	29,197,320.900	120,900,944.50	25,450,948.23
Financial expenses	21,120,392.55	-50,372.710	16,909,783.61	1,244,677.38
Losses of devaluation of asset	-299,649.37	-583,457.620	-929,312.15	2,877,419.49
Add: Changing income of fair value(Loss is listed with “-”)				
Investment income (Loss is listed with “-”)	30,884,232.73	-1,099,694.240	6,848,265.00	666,480.77
Including: Investment income on affiliated company and joint venture	-1,099,695.79	-1,099,694.890	412,920.57	666,480.77
Exchange income (Loss is listed with “-”)				
III. Operating profit (Loss is listed with “-”)	144,772,280.96	-1,027,657.49	98,189,158.15	-6,166,080.75
Add: Non-operating income	3,169,190.78	87,670.91	707,479.74	42,953.03
Less: Non-operating expense	1,250,980.44	49,209.60	1,007,171.78	6,284.07
Including: Disposal loss of non-current asset	186,323.58			
IV. Total Profit (Loss is listed with “-”)	146,690,491.30	-989,196.18	97,889,466.11	-6,129,411.79
Less: Income tax	37,251,937.17		25,515,705.53	
V. Net profit (Net loss is listed with “-”)	109,438,554.13	-989,196.18	72,373,760.58	-6,129,411.79
Net profit attributable to owner’s equity of parent company	103,076,826.65	-989,196.18	67,992,670.48	
Minority shareholders’ gains and losses	6,361,727.48		4,381,090.10	
VI. Earnings per share				
i. Basic earnings per share	0.358		0.236	
ii. Diluted earnings per share	0.358		0.236	

4.4 Cash flow statement from year-begin to end of report period

Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. July-Sep., 2007 Unit: RMB

Items	This period		Same period of last year	
	Consolidation	Parent Company	Consolidation	Parent Company
I. Cash flows arising from operating activities:				
Cash received from selling commodities and providing labor services	5,139,351,239.05	985,214,430.72	4,159,918,713.11	947,122,932.74
Net increase of customer deposit and interbank deposit				
Net increase of loan from central bank				
Net increase of capital borrowed from other financial institution				
Cash received from original insurance contract fee				
Net cash received from reinsurance business				
Insured savings and net increase of investment				
Net increase of disposal of transaction financial asset				
Cash received from interest, commission charge and commission				
Net increase of capital borrowed				
Net increase of returned business capital				
Write-back of tax received	2,856,832.26	71,219.60	413,249.74	88,258.55
Other cash received concerning operating activities	106,402,921.83	30,631,685.64	63,138,318.18	15,577,071.13
Subtotal of cash inflow arising from operating activities	5,248,610,993.14	1,015,917,335.96	4,223,470,281.03	962,788,262.42
Cash paid for purchasing commodities and receiving labor service	4,637,779,394.55	1,024,571,499.06	3,543,625,041.54	874,867,883.05
Net increase of customer loans and advances				
Net increase of deposits in central bank and interbank				
Cash paid for original insurance contract compensation				

Cash paid for interest, commission charge and commission				
Cash paid for bonus of guarantee slip				
Cash paid to/for staff and workers	185,603,471.69	20,601,135.52	162,340,183.97	18,544,413.05
Taxes paid	129,909,676.36	16,258,540.22	130,740,859.13	8,044,593.25
Other cash paid concerning operating activities	214,327,673.72	30,934,208.68	207,427,827.52	30,480,317.11
Subtotal of cash outflow arising from operating activities	5,167,620,216.32	1,092,365,383.48	4,044,133,912.16	931,937,206.46
Net cash flows arising from operating activities	80,990,776.82	-76,448,047.52	179,336,368.87	30,851,055.96
II. Cash flows arising from investing activities:				
Cash received from recovering investment	26,592,039.70	0.65	123,724.85	
Cash received from investment income	3,457,479.92	97,150,558.31	2,822,107.65	62,278,540.50
Net cash received from disposal of fixed, intangible and other long-term assets	1,949,760.00	625,720.00	156,822.20	76,630.00
Net cash received from disposal of subsidiaries and other units				
Other cash received concerning investing activities				
Subtotal of cash inflow from investing activities	31,999,279.62	97,776,278.96	3,102,654.70	62,355,170.50
Cash paid for purchasing fixed, intangible and other long-term assets	57,603,104.98	2,562,473.00	92,027,369.92	982,320.70
Cash paid for investment			71,870,565.95	116,531,100.00
Net increase of mortgaged loans				
Net cash received from subsidiaries and other units				
Other cash paid concerning investing activities				
Subtotal of cash outflow from investing activities	57,603,104.98	2,562,473.00	163,897,935.87	117,513,420.70
Net cash flows arising from investing activities	-25,603,825.36	95,213,805.96	-160,795,281.17	-55,158,250.20
III. Cash flows arising from				

financing activities				
Cash received from absorbing investment				
Including: Cash received from absorbing minority shareholders' investment by subsidiaries				
Cash received from loans	176,000,000.00	40,000,000.00	274,520,000.00	20,000,000.00
Cash received from issuing bonds				
Other cash received concerning financing activities	68,423,107.71	132,825,593.92	122,953,723.83	188,083,224.27
Subtotal of cash inflow from financing activities	244,423,107.71	172,825,593.92	397,473,723.83	208,083,224.27
Cash paid for settling debts	188,000,000.00	5,000,000.00	303,800,000.00	20,000,000.00
Cash paid for dividend and profit distributing or interest paying	86,755,768.30	24,831,128.37	33,702,730.98	7,599,767.20
Including: Dividend and profit of minority shareholder paid by subsidiaries				
Other cash paid concerning financing activities	13,743,923.54	161,587,638.92	54,461,001.54	197,515,854.63
Subtotal of cash outflow from financing activities	288,499,691.84	191,418,767.29	391,963,732.52	225,115,621.83
Net cash flows arising from financing activities	-44,076,584.13	-18,593,173.37	5,509,991.31	-17,032,397.56
IV. Influence on cash due to fluctuation in exchange rate	-50.28	-50.28	-5,832.80	-1,172.32
V. Net increase of cash and cash equivalents	11,310,317.05	172,534.79	24,045,246.21	-41,340,764.12
Add: Balance of cash and cash equivalents at the period -begin	205,341,835.52	51,149,747.14	169,288,045.66	75,509,035.69
VI. Balance of cash and cash equivalents at the period -end	216,652,152.57	51,322,281.93	193,333,291.87	34,168,271.57

4.5 Auditor' report

Auditor's opinions: Un-audited